About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMRN - Amarin Corporation p...| Previous Close | $7.00 | Open | $7.06 |
| Volume | 2.77M | Market Cap | 2.72B |
| Yield | Last Dividend |
| Amarin???s Vascepa To Take Part In Covid... | 08/09/20 |
| Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of its lead product Vascepa ... | |
| Amarin Corporation plc (AMRN) Q2 2020 Ea... | 08/05/20 |
| Amarin Corporation plc (NASDAQ: AMRN) Q2 2020 earnings call dated Aug. 04, 2020 Corporate Participants: Elisabeth Schwartz -- Senior Director of Inves... | |
| Amarin (AMRN) Q2 2020 earnings call: Foc... | 08/05/20 |
| Amarin (NASDAQ: AMRN) reported second quarter 2020 results yesterday. During the earnings conference call, the management and the analysts discussed m... | |
| Amarin (AMRN) Q2 2020 earnings call: Foc... | 08/05/20 |
| Amarin (NASDAQ: AMRN) reported second quarter 2020 results yesterday. During the earnings conference call, the management and the analysts discussed m... | |
| Amarin Reports Mixed Q2 As COVID-19 Weig... | 08/04/20 |
| Amarin Corporation plc (NASDAQ: AMRN ) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results. What Happened: ... | |
| Is European Update Overshadowing Amarin?... | 08/04/20 |
| No summary available. | |
| Amarin (AMRN) maintains revenue growth d... | 08/04/20 |
| Amarin Corporation plc (NASDAQ:AMRN) reported second quarter 2020 earnings results today. The company reported a 34% growth in total revenue to $135.3... | |
| Amarin : Investor Deck to Accompany Q2'2... | 08/04/20 |
| Second Quarter 2020 Financial and Operational Results Slides to Accompany Investor Conference Call August 4, 2020 NASDAQ: AMRN ??? | August 4, 2020 | |
| Recap: Amarin Q2 Earnings | 08/04/20 |
| Shares of Amarin Corp (NASDAQ:AMRN) rose 2.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were u... | |
| The Week Ahead In Biotech: Novavax Coron... | 08/02/20 |
| Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flo... | |
| Amarin to Report Second Quarter 2020 Res... | 07/21/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a??? | |
| Amarin (AMRN) stock to remain within a t... | 06/24/20 |
| The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin. Shares o... | |
| Amarin Analysts Say Vascepa Patent Settl... | 06/17/20 |
| Amarin Corporation plc (NASDAQ: AMRN ) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic ve... | |
| The Daily Biotech Pulse: Patent Win For ... | 06/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC ... | |
| Amarin Announces Patent Litigation Settl... | 06/16/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement w... | |
| Why Some Analysts Remain Bullish on Amar... | 06/16/20 |
| No summary available. | |
| Why Amarin (AMRN) Stock Might be a Great... | 06/09/20 |
| Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| What Amarin Stock Investors Will Hear at... | 06/09/20 |
| No summary available. | |
| Will New Marketing Push Pump Amarin Stoc... | 06/02/20 |
| No summary available. | |
| Amarin Plans to Increase VASCEPA?? (icos... | 06/01/20 |
| Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Red... | |
| Potential COVID-19 Treatment Could Help ... | 05/27/20 |
| No summary available. | |
| Generic Threat To Amarin's Vascepa Overr... | 05/22/20 |
| Amarin Corporation plc (NASDAQ: AMRN ) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a thir... | |
| Amarin Stock???s Potential Unhampered by... | 05/22/20 |
| No summary available. | |
| Amarin Stock Is Falling. A Competitor Go... | 05/22/20 |
| British generic drugmaker Hikma Pharmaceuticals said it had received Food and Drug Administration approval to sell a generic version of Amarin???s fis... | |
| Amarin Down 10% in Pre-Market On Generic... | 05/22/20 |
| Shares in Amarin (AMRN) are plunging 10% in Friday???s pre-market trading on the news that Hikma Pharmaceuticals (HKMPY) has received approval from th... | |
| Amarin Supports Trial to Investigate the... | 05/21/20 |
| DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical??... | |
| Will Amarin Stock???s Fundamentals Outwe... | 05/19/20 |
| No summary available. | |
| Huge Sales Growth Brightens Future for A... | 05/13/20 |
| No summary available. | |
| Why an Appeals Court May Hold Key to Ama... | 05/08/20 |
| No summary available. | |
| Amarin's (AMRN) Q1 Loss In Line With Est... | 05/01/20 |
| Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa. | |
| Date | 2020-08-04 (BMO) | Est. (EPS/Rev.) | ($0.07)/ 149.48M |
| Actual (EPS/Rev.) | $0.01/ $135.32 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Options Eagle | George | 79.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Option short-term trading [Unusual] | Debashis K | 66.00 % | Subscribe |
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
